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ABSTRACT: A naphthalimide-based two-photon probe 
(AHGa) for the detection of cell senescence is designed. The 
probe contains a naphthalimide core, an L-histidine methyl ester 
linker and an acetylated galactose bonded to one of the aromatic 
nitrogen atoms of the L-histidine through a hydrolysable N-
glycosidic bond. Probe AHGa is transformed into AH in senes-
cent cells resulting in an enhanced fluorescent emission intensity. 
In vivo detection of senescence is validated in mice bearing tumor 
xenografts treated with senescence-inducing chemotherapy.  
 
The main purpose of cellular senescence is to prevent the prolif-
eration of damaged or stressed cells and to trigger tissue repair.1 
However, upon persistent damage or during aging, the dynamic 
process of tissue repair becomes inefficient and senescent cells 
tend to accumulate. This accumulation in tissues is believed to 
impair tissue functions and accelerate aging.1 Several markers and 
phenotypic characteristics have been described to define senes-
cence: (i) a complex paracrine response termed as senescence-
associated secretory phenotype (SASP),2 (ii) the expression of cell 
cycle inhibitors and/or tumor suppressors (p16, p21 or p53)3 and 
(iii) high levels of lysosomal β-galactosidase (βGal) activity4 and 
other hydrolases.5 
It has been demonstrated that genetic ablation of senescent cells 
ameliorates a variety of ageing-associated diseases, reverts long-
term degenerative processes and extends longevity.6 Inspired by 
these findings, strategies to prevent, replace or remove senescent 
cells have become of interest. For instance, there is an increasing 
interest in the development of senolytic molecules able to induce 
apoptosis preferentially in senescent cells.7,8 A related key issue in 
this field, is the design of probes to accurately detect senescent 
cells in aged or damaged tissues.1 However, one of the major 
obstacles limiting progress in this research area, is the nearly lack 
of real-time methods to selectively track senescence in in vivo 
systems. 
 











Detection of senescent cells usually relies on the detection of 
senescence-associated βgal (SAβgal), and several fluorescent or 
chromogenic probes have been reported for the visualization of 
this enzymatic activity.9 However, these first-generation probes 
are usually unsuitable for in vivo imaging as they rely on chromo-
genic changes or on the use of classical one-photon fluorescence 
excitation. As an alternative, recent stimulating studies developing 
two-photon fluorescent probes for the visualization of βgal activi-
ty have been described (Table S1).10 However, some of the re-
ported probes are synthesized by using tedious multistep proto-
cols. Another common drawback is the fact that probes are tested 
in cultured cells or in animal models that were not directly related 
to senescence. The methodology used in these studies, is based on 
a lacZ gene transfection, which results in high levels of bacterial 
βgal expression in the cell cytoplasm (unlike the lysosomal βgal 
activity associated with senescent cells).11 A limited number of 
works describe the use of human cell lines overexpressing endog-
enous βgal per se, as it is the case of ovarian cancer cell lines.12 
However, these cancer cell lines are obviously not senescent 







































studies with mice, probes are tested in models that (i) labeled 
tumors with avidin-βgal13 or (ii) transfected tumor cells with 
pCMV-lacZ plasmid.14 In both cases a bacterial βgal overexpres-
sion is achieved. In this scenario, the development reliable two-
photon fluorescence-based probes for in vivo detection of senes-




Figure 1. a) Schematic representation of AHGa activation in 
senescent cells. b) Emission spectra of PBS (pH 4.5)-DMSO 
(0.01%) solutions of 10-5 M AHGa (blue) and AH (orange) when 
excited at 405 nm. 
 
 
In view of the aspects mentioned above, we report herein a nov-
el molecular probe for the two-photon fluorogenic in vivo detec-
tion of senescence. The probe (AHGa) is based on a naph-
thalimide fluorophore as signaling unit containing an L-histidine 
methyl ester linker and an acetylated galactose attached to one of 
the aromatic nitrogen atoms of the L-histidine through a hydrolys-
able N-glycosidic bond. Probe AHGa is transformed into AH in 
senescent cells (Figure 1a) resulting in an enhanced fluorescent 
emission intensity. In vivo detection of senescence was demon-
strated in mice bearing tumor xenografts treated with senescence-
inducing chemotherapy. 
AHGa was easily prepared using a two-step protocol (Scheme 
1). 4-bromo-1,8-naphtalic anhydride (A) and L-histidine methyl 
ester (H) were reacted in refluxing dioxane yielding fluorophore 
AH. Then, a nucleophilic substitution reaction between AH and 
2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl bromide (Ga) yield-
ed the AHGa probe. Both, AH and AHGa, were fully character-
ized (Figures S1-S6.). Figure 1b summarizes the fluorogenic 
behavior of AHGa and AH. Excitation at 405 nm of AHGa in 
PBS (pH 4.5)-DMSO (0.01%) did not show any emission band 
(ɸAHGa = 0.002), whereas under the same experimental conditions 
AH displayed an intense fluorescence (ɸAH = 0.458, 286-fold 
enhancement) at 540 nm (Figure 1b and S7). Moreover, the emis-
sion intensity of AH remained unchanged in the 4-8 pH range 
(Figure S8). 
Targeting of senescent cells in vitro with AHGa was validated 
with the SK-MEL-103 (human melanoma) cell line treated with 





Figure 2. (a, e) Conventional X-Gal chemical assay for SAβGal expression of control (a) and palbociclib-treated (senescent) (e) SK-MEL-
103 cells. (b, f) Bright channel for control SK-MEL-103 (b) and senescent SK-MEL-103 (f) cells. (c, d, g, h) Two-photon images of (c, d) 
control SK-MEL-103 and (g, h) senescent SK-MEL-103 cells in the absence (c, g) and in the presence (d, h) of AHGa probe. Cells were 
incubated with AHGa (10 µM) with DMEM (10% FBS, 0.1% DMSO) in 20% O2 and 5% CO2 at 37°C for 2 h, and images were acquired 
by using a femtosecond pulse laser (excitation at 750 nm). Representative images from repeated experiments (n = 3) are shown. (i) Quanti-
fication of the fluorescence emission intensity of control and palbociclib-treated SK-MEL-103 cells incubated with AHGa. Inset: Basal 
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Figure 3. (a,b) Tissue portions of SK-MEL-103 control tumors (a) or SK-MEL-103 senescent tumors after whole-mount SAβGal staining. 
(c-f) Confocal images of representative portions of SK-MEL-103 control tumors (c,d) and SK-MEL-103 senescent tumors (e,f) vehicle 
(c,e) and after intravenous tail injection (d,f) of AHGa probe (10 mg/ml, 200 µl). Mice were sacrificed at 3 hours post-treatment. (g) Quan-
tification of the fluorescence emission intensity of SK-MEL-103 (control) and SK-MEL-103 treated with palbociclib (senescent) in the 
absence or in the presence of the AHGa probe. Inset: Basal fluorescence is represented in white bars and AH ascribed fluorescence is 
represented in red. Error bars represent s.d. (n = 6 tumors for each condition). 
 
Palbociclib is a CDK4/6 inhibitor which has been displayed to 
induce cell cycle arrest in melanoma cells.15 In a common exper-
iment, SK-MEL-103 cells were treated with 5 µM palbociclib 
during two weeks in order to induce senescence (Figure 2b and 
2f). After this treatment, cellular senescence in SK-MEL-103 
cells was assessed by SAβGal activity assay16 (Figure 2a and 2e). 
Moreover it was found that AH and AHGa proved to be not toxic 
for both control and palbociclib-treated SK-MEL-103 cells after 
48 h at concentrations of up to 20 µM (Figure S9). 
Both, control and palbociclib-treated SK-MEL-103 cells were 
seeded in flat-bottom-clear 96 well plates and incubated with a 
solution containing AHGa (10 µM in DMEM, 0.1% DMSO) for 
2 h. Cells were then analyzed by two-photon confocal microscopy 
using 750 nm as excitation wavelength. Control SK-MEL-103 
cells in the absence (Figure 2c) or presence (Figure 2d) of AHGa 
did not exhibit any noticeable fluorescence signal. Similarly, in 
the absence of the probe, senescent SK-MEL-103 cells did not 
show significant auto-fluorescence (Figure 2g). In contrast, senes-
cent cells treated with AHGa showed a clear bright emission 
(Figure 2h) due to the presence of an emission band at ca. 540 
nm, and attributed to the hydrolysis of AHGa into AH that selec-
tively occurred in senescent cells. The quantification of the fluo-
rescence associated to AH was also determined for each treatment 
from confocal images (Figure 2i). A remarkable fluorescence 
enhancement (ca. 10-fold) for palbociclib-treated SK-MEL-103 
cells in the presence of AHGa when compared with control SK-
MEL-103 cells was observed.  
Once assessed the activation of AHGa in senescent cultured 
cells, the probe was validated in mice bearing tumor xenografts 
treated with senescence-inducing chemotherapy. In a typical 
experiment, tumor xenografts were generated by injecting subcu-
taneously SK-MEL-103 melanoma cells. Upon tumor formation, 
mice were treated daily with palbociclib for 10 days in order to 
induce senescence and arrest tumor growth. Finally, AHGa probe 
was injected intravenously in the tail vain and mice were sacri-
ficed at 3 h after the treatment. Tumors were extracted and cellu-
lar senescence was assessed by a SAβGal staining (Figure 3b). 
The absence of the proliferative marker Ki67, and the reduction in 
phosphorylated Rb in tumors were also indicative of senescence.17 
Then, fresh tumor sections were analyzed using confocal micros-
copy (Figures 3c-3f). Control tumors showed negligible fluores-
cence either in the absence or in the presence of AHGa (Figures 
3c and 3d). Tumors from mice treated with palbociclib in the 
absence of the probe were used as a control for tissue auto-
fluorescence, and showed a weak emission (Figure 3e). In sharp 
contrast, isolated tumors from mice treated with palbociclib and 
intravenously injected with AHGa showed a strong fluorescent 
signal (Figure 3f). Quantification of the associated AH fluores-
cence was determined for each condition (Figure 3g). A marked 
emission enhancement (ca. 15-fold) in tumors treated with palbo-
ciclib compared to control tumors was observed. In addition, ex 
vivo imaging of fresh sections from different organs showed that 
emission from AH was only observed in senescent tumors (Figure 
S10).  
Altogether, we describe a two-photon fluorescent probe 
(AHGa) for the in vivo detection of cell senescence. Targeting of 
senescent cells in vitro with AHGa was validated with the SK-
MEL-103 cancer cell line treated with palbociclib. A remarkable 
fluorescence emission enhancement (ca. 10-fold) in the presence 
of AHGa for palbociclib-treated SK-MEL-103 (senescent) cells 
was observed when compared with control SK-MEL-103 cells, 
due to the formation of AH. The ability of tracking senescence of 
probe AHGa was also studied in vivo by employing mice bearing 
subcutaneous tumor xenografts generated with SK-MEL-103 
melanoma cells and treated with palbociclib. Tumors in palbo-
ciclib-untreated mice showed negligible fluorescence emission 
both in the absence or in the presence of AHGa, whereas tumors 
in mice treated with palbociclib and intravenously injected with 
AHGa showed a clear fluorescent signal. A marked emission 
enhancement (ca. 15-fold) in tumors treated with palbociclib 
compared to non-treated tumors was observed. AH fluorescence 
was only found in senescent tumors but not in other organs. The 
combination of selectivity, sensitivity and straightforward synthe-
sis make AHGa and efficient OFF-ON two-photon probe for the 
in vivo signaling of senescence.  
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